Forest lab has sued Glenmark Pharma for Savella patent infringement. New York-based Forest has claimed that that Glenmark's abbreviated new drug application for the sale of milnacipran hydrochloride in 12.5, 25, 50 and 100 milligram dosage strengths would infringe on several patents it holds that indicate methods for treating fibromyalgia. Those patents are not due to expire until at least 2021.
Savella, or milnacipran hydrochloride, is a serotonin-norepinephrine reuptake inhibitor used to treat fibromyalgia, a disease characterized by chronic widespread pain throughout the body.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
